Hyafelic Uno
Commercial- Indications
- Knee osteoarthritis
Company intelligence / Profile preview
Felixida Biotech
San Francisco, California, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Commercial
01
Overview
Felix Biotechnology is developing inhalable bacteriophage therapies targeting chronic, drug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. Their lead program, YPT-01, is being evaluated in a Phase 1/2 trial at Yale. The company’s platform uses machine learning and CRISPR-based tools to design and engineer custom phages with expanded host range and reduced resistance risk. Early funding from the Cystic Fibrosis Foundation supports preclinical and early clinical development.[4][5][7]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Bacteriophage therapy (phage therapy)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Yale University (foundational research/licensing)[3][4]UC Berkeley (collaborative research)[3]
Beyond the preview
Go deeper on Felixida Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Felixida Biotech.